• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CAREFUSION 213, LLC 0113 CHLORAPREP SEPP; 2% W/V CHLORHEXIDINE GLUCONATE/70% V/V ISOPROPYL ALCOHOL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CAREFUSION 213, LLC 0113 CHLORAPREP SEPP; 2% W/V CHLORHEXIDINE GLUCONATE/70% V/V ISOPROPYL ALCOHOL Back to Search Results
Catalog Number 270449
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Abrasion (1689)
Event Date 03/24/2021
Event Type  Injury  
Manufacturer Narrative
(b)(4).Initial emdr submission.A follow up emdr will be submitted if additional information becomes available.(b)(4).
 
Event Description
It was reported that two members of the staff have had a sharps injury due to the glass breaking through the plastic.Per complaint form: i spoke to (b)(6) on the phone they are in radiology and used the chloraprep sepp that is part of the rocialle cannulation pack that is used in wales.They have used the product for a long time but two members of staff have had a sharps injury due to the glass breaking through the plastic.Also below please see the initial communication sent to me via the product manager.Contact info omitted.Business unit: infection prevention.Product line: chloraprep.Enquiry: a couple of my staff and cut their fingers recently using chloraprep sepp 0.67ml.This could be a batch issue? batch number 8264564.
 
Manufacturer Narrative
No photos or samples were available for evaluation.Unfortunately, as a result, bd was unable to verify the reported issue or define a root cause.If samples or photos become available, this record will be re-opened and re-assessed.Production record review was completed for batch/lot 8264564 and no non-conformities, failures, deviations, or rework activities occurred during the manufacturing of this lot similar to the reported issue or that could have contributed to the reported failure mode.No further action will be taken based on no adverse trend observed and will continue to be tracked and trended.
 
Event Description
It was reported that two members of the staff have had a sharps injury due to the glass breaking through the plastic.Per complaint form: i spoke to helen on the phone they are in radiology and used the chloraprep sepp that is part of the rocialle cannulation pack that is used in wales.They have used the product for a long time but two members of staff have had a sharps injury due to the glass breaking through the plastic.Also below please see the initial communication sent to me via the product manager.Contact info omitted.Business unit: infection prevention.Product line: chloraprep.Enquiry: a couple of my staff and cut their fingers recently using chloraprep sepp 0.67ml.This could be a batch issue? batch number 8264564.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CHLORAPREP SEPP
Type of Device
2% W/V CHLORHEXIDINE GLUCONATE/70% V/V ISOPROPYL ALCOHOL
Manufacturer (Section D)
CAREFUSION 213, LLC 0113
1550 northwestern dr
el paso TX 79912
MDR Report Key11711456
MDR Text Key252358503
Report Number3004932373-2021-00209
Device Sequence Number1
Product Code KXG
Combination Product (y/n)Y
PMA/PMN Number
EXEMPT
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,other
Type of Report Initial,Followup
Report Date 07/30/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date09/30/2021
Device Catalogue Number270449
Device Lot Number8264564
Initial Date Manufacturer Received 04/07/2021
Initial Date FDA Received04/22/2021
Supplement Dates Manufacturer Received07/30/2021
Supplement Dates FDA Received07/30/2021
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age31 YR
-
-